Fresenius SE & Co KGaA (FRE):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Fresenius SE & Co KGaA (FRE) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7416
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥68,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥102,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Fresenius SE & Co KGaA (Fresenius) is a global health care group, which offers products and services for dialysis treatment. It provides various dialysis services through its own clinics and sells its products to other dialysis service providers. Its major products and services includes machines for hemodialysis, acute dialysis and peritoneal dialysis; solutions for infusion therapy; dialysis care services; Spectra laboratories; liver support therapy services; and provision projects and services for hospitals and other health care facilities. It also operates and manages acute care and postacute care hospitals in Germany through Helios Kliniken Group. Its major manufacturing plants are in the US, Germany, China, Sweden and Japan. Fresenius conducts operations in Asia-Pacific, Europe, Africa and the Americas. The company is headquartered in Bad Homburg, Hessen, Germany.

Fresenius SE & Co KGaA (FRE) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
Fresenius SE & Co KGaA, Medical Equipment Deals By Type, 2012 to YTD 2018 8
Fresenius SE & Co KGaA, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
Fresenius SE & Co KGaA, Medical Equipment, Deals By Market, 2012 to YTD 2018 10
Fresenius SE & Co KGaA, Medical Equipment, Deals Summary, 2012 to YTD 2018 11
Fresenius SE & Co KGaA, Medical Equipment, Deal Details 13
Asset Purchase 13
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 13
Partnerships 14
Fresenius Medical Care and Humacyte Enter into Partnership Agreement 14
RenalSense Enters into Distribution Agreement with Fresenius Medical Care 15
Debiotech and Fresenius Medical Care Enter into Agreement 16
Verax Biomedical Renews its Commercialization Agreement with Fresenius Kabi USA 17
Sequana Medical Enters into Distribution Agreement with Fresenius Medical Care 18
Toray Industries Enters into Distribution Agreement with Fresenius Medical Care 19
HemaTerra Technologies Enters Into Co-Development Agreement With Fenwal 20
Fenwal Enters Into Co-Marketing Agreement With Applied Science 21
JMS North America Enters Into Distribution Agreement With Fresenius Medical Care For AVF Needles 22
Equity Offering 23
Humacyte to Raise USD150 Million in Equity Financing 23
Fresenius Plans Private Placement Of Shares For US$1.3 Billion 24
Debt Offering 25
Fresenius Raises USD530.4 Million in Private Placement of 3% Notes Due 2032 25
Fresenius Raises USD742.5 Million in Private Placement of 0.875% Notes Due 2022 26
Fresenius Raises USD742.5 Million in Private Placement of 1.5% Notes Due 2024 27
Fresenius Raises USD742.5 Million in Private Placement of 2.125% Notes Due 2027 28
Fresenius Raises USD300 Million in Private Placement of Notes 29
Fresenius Medical Care Raises USD400 Million in Private Placement of 4.75% Notes Due 2024 30
Fresenius Medical Care Raises USD500 Million in Private Placement of 4.125% Notes Due 2020 31
Fresenius Medical Care Raises USD518 Million in Private Placement of Convertible Bonds 32
Fresenius Increases Size Of Private Placement Of Notes Due 2024 For US$611.4 Million 33
Fresenius Completes Private Placement Of Notes Due 2019 For US$407.6 Million 34
Fresenius Completes Private Placement Of Notes Due 2021 For US$611.4 Million 35
Fresenius Medical Care Prices Private Placement Of Notes Due 2020 For US$673 Million 36
Fresenius Medical Care Completes Private Placement Of 5.625% Senior Unsecured Notes Due 2019 For US$800 Million 38
Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2019 For US$316.4 Million 39
Fresenius Medical Care Completes Private Placement Of 5.875% Senior Unsecured Notes Due 2022 For US$700 Million 40
Asset Transactions 41
Fresenius Medical to Divest Dialysis Services Unit in Venezuela 41
Fresenius Medical Care Divests Fresenius Medical care Dialysis Clinic for USD1.4 Million 42
Acquisition 43
Quest Diagnostics Acquires Shiel Medical from Fresenius Medical 43
Fresenius Medical Care to Acquire NxStage Medical for up to USD2 Billion 45
Fresenius Medical Care Acquires Xenios 47
Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For US$1.1 Billion 48
Fresenius Acquires 70% Stake In Huangshi Lishizhen Medicine Group Wuhan Xisu Pharma From Huangshi Lishizhen Medicine Group Wuhan Lishizhen Medicine 50
Fresenius SE & Co KGaA – Key Competitors 51
Fresenius SE & Co KGaA – Key Employees 52
Fresenius SE & Co KGaA – Locations And Subsidiaries 53
Head Office 53
Other Locations & Subsidiaries 53
Recent Developments 56
Strategy And Business Planning 56
Jun 27, 2018: Fresenius Kabi expanding operations at UK site 56
May 09, 2018: Fresenius holds topping-out ceremony for new ‘EK3’ building at headquarters in Bad Homburg 57
Mar 22, 2018: Fresenius starts work on new RD building in Bad Homburg 58
Sep 29, 2017: Fresenius lays cornerstone for new building at headquarters in Bad Homburg 59
Jun 08, 2017: Fresenius Medical Care sees excellent prospects for further growth and launches a new Global Efficiency Program at its Capital Markets Day 2017 60
Mar 20, 2017: Fresenius Helios opens new hospital building in Duisburg 61
Financial Announcements 62
May 03, 2018: Fresenius makes excellent start to 2018, with strong sales and net income growth in constant currency 62
May 03, 2018: Fresenius Medical Care remains on track for another record year after solid first quarter 2018 67
Feb 26, 2018: Fresenius remains on growth course after 14 straight record years 71
Aug 01, 2017: Fresenius confirms its guidance after a strong second quarter with double-digit sales and earnings growth 78
May 03, 2017: Fresenius is off to an excellent start to the year with strong sales and earnings growth 81
Feb 22, 2017: Fresenius reports 13th consecutive record year and targets continued strong growth 87
Corporate Communications 92
May 18, 2018: Fresenius on track to continue strong growth, 25th straight dividend increase approved 92
May 02, 2018: Fresenius Medical Care Announces Leadership Change in EMEA 93
Jul 21, 2017: Fresenius appoints Rachel Empey as Chief Financial Officer 94
Jan 13, 2017: Fresenius Medical Care Announces Leadership Change in North America 95
Legal and Regulatory 96
Jan 31, 2017: Fresenius Medical Care reaches agreement on outstanding payments 96
Jan 26, 2017: U.S. District Court Issues Preliminary Injunction Against Premium Assistance Regulation 97
Other Significant Developments 98
May 17, 2018: Fresenius Medical Care forecasts continued strong growth 98
Jul 12, 2017: Fresenius Medical Care successfully amends and extends its credit agreement, ahead of schedule 99
Appendix 100
Methodology 100
About GlobalData 100
Contact Us 100
Disclaimer 100

List of Tables
Fresenius SE & Co KGaA, Medical Equipment, Key Facts, 2017 2
Fresenius SE & Co KGaA, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
Fresenius SE & Co KGaA, Medical Equipment Deals By Type, 2012 to YTD 2018 8
Fresenius SE & Co KGaA, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
Fresenius SE & Co KGaA, Deals By Market, 2012 to YTD 2018 10
Fresenius SE & Co KGaA, Medical Equipment, Deals Summary, 2012 to YTD 2018 11
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 13
Fresenius Medical Care and Humacyte Enter into Partnership Agreement 14
RenalSense Enters into Distribution Agreement with Fresenius Medical Care 15
Debiotech and Fresenius Medical Care Enter into Agreement 16
Verax Biomedical Renews its Commercialization Agreement with Fresenius Kabi USA 17
Sequana Medical Enters into Distribution Agreement with Fresenius Medical Care 18
Toray Industries Enters into Distribution Agreement with Fresenius Medical Care 19
HemaTerra Technologies Enters Into Co-Development Agreement With Fenwal 20
Fenwal Enters Into Co-Marketing Agreement With Applied Science 21
JMS North America Enters Into Distribution Agreement With Fresenius Medical Care For AVF Needles 22
Humacyte to Raise USD150 Million in Equity Financing 23
Fresenius Plans Private Placement Of Shares For US$1.3 Billion 24
Fresenius Raises USD530.4 Million in Private Placement of 3% Notes Due 2032 25
Fresenius Raises USD742.5 Million in Private Placement of 0.875% Notes Due 2022 26
Fresenius Raises USD742.5 Million in Private Placement of 1.5% Notes Due 2024 27
Fresenius Raises USD742.5 Million in Private Placement of 2.125% Notes Due 2027 28
Fresenius Raises USD300 Million in Private Placement of Notes 29
Fresenius Medical Care Raises USD400 Million in Private Placement of 4.75% Notes Due 2024 30
Fresenius Medical Care Raises USD500 Million in Private Placement of 4.125% Notes Due 2020 31
Fresenius Medical Care Raises USD518 Million in Private Placement of Convertible Bonds 32
Fresenius Increases Size Of Private Placement Of Notes Due 2024 For US$611.4 Million 33
Fresenius Completes Private Placement Of Notes Due 2019 For US$407.6 Million 34
Fresenius Completes Private Placement Of Notes Due 2021 For US$611.4 Million 35
Fresenius Medical Care Prices Private Placement Of Notes Due 2020 For US$673 Million 36
Fresenius Medical Care Completes Private Placement Of 5.625% Senior Unsecured Notes Due 2019 For US$800 Million 38
Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2019 For US$316.4 Million 39
Fresenius Medical Care Completes Private Placement Of 5.875% Senior Unsecured Notes Due 2022 For US$700 Million 40
Fresenius Medical to Divest Dialysis Services Unit in Venezuela 41
Fresenius Medical Care Divests Fresenius Medical care Dialysis Clinic for USD1.4 Million 42
Quest Diagnostics Acquires Shiel Medical from Fresenius Medical 43
Fresenius Medical Care to Acquire NxStage Medical for up to USD2 Billion 45
Fresenius Medical Care Acquires Xenios 47
Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For US$1.1 Billion 48
Fresenius Acquires 70% Stake In Huangshi Lishizhen Medicine Group Wuhan Xisu Pharma From Huangshi Lishizhen Medicine Group Wuhan Lishizhen Medicine 50
Fresenius SE & Co KGaA, Key Competitors 51
Fresenius SE & Co KGaA, Key Employees 52
Fresenius SE & Co KGaA, Other Locations 53
Fresenius SE & Co KGaA, Subsidiaries 53

List of Figures
Fresenius SE & Co KGaA, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Fresenius SE & Co KGaA, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Fresenius SE & Co KGaA, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
Fresenius SE & Co KGaA, Medical Equipment, Deals by Type, 2012 to YTD 2018 8
Fresenius SE & Co KGaA, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
Fresenius SE & Co KGaA, Medical Equipment, Deals by Market, 2012 to YTD 2018 10

★海外企業調査レポート[Fresenius SE & Co KGaA (FRE):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kinross Gold Corporation:企業のM&A・事業提携・投資動向
    Kinross Gold Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kinross Gold Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • ImmunoCellular Therapeutics Ltd (IMUC)-医療機器分野:企業M&A・提携分析
    Summary ImmunoCellular Therapeutics Ltd (IMCU) is a clinical-stage biotechnology company which develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented monoclonal antibodies. IMCU’s immunotherapies product …
  • ACTIVE Network, LLC:企業のM&A・事業提携・投資動向
    ACTIVE Network, LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ACTIVE Network, LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Celgene Corp (CELG)-製薬・医療分野:企業M&A・提携分析
    Summary Celgene Corp (Celgene) is an integrated global biopharmaceutical company that carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immune-inflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaz …
  • AGCO Corporation:企業の戦略・SWOT・財務分析
    AGCO Corporation - Strategy, SWOT and Corporate Finance Report Summary AGCO Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Capital Power Corporation (CPX)-エネルギー分野:企業M&A・提携分析
    Summary Capital Power Corporation (CPC) is a power producer that develops, acquires, operates, optimizes, and builds power generation facilities. It generates electricity from energy-efficient technology, lower-carbon fuel, and renewable sources using a range of energy sources. The company owns supe …
  • Dairygold Co-operative Society Ltd:企業の戦略的SWOT分析
    Dairygold Co-operative Society Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Forum Energy Metals Corp (FDC):企業の財務・戦略的SWOT分析
    Summary Forum Energy Metals Corp (Forum Energy) formerly Forum Uranium Corp, is a mining and mineral resource company. The company acquires, explores, and develops energy metals, such as uranium and copper in Saskatchewan’s Athabasca Basin. Its projects include Janice Lake Sedimentary Copper Project …
  • Duke Energy Indiana, LLC:発電所・企業SWOT分析
    Duke Energy Indiana, LLC - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Elekeiroz SA (ELEK3):企業の財務・戦略的SWOT分析
    Elekeiroz SA (ELEK3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Nichirei Corporation:企業の戦略・SWOT・財務分析
    Nichirei Corporation - Strategy, SWOT and Corporate Finance Report Summary Nichirei Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Castlight Health Inc (CSLT):医療機器:M&Aディール及び事業提携情報
    Summary Castlight Health Inc (Castlight) provides an online health navigation platform that connects patients with health vendors, plan designs, and benefit resources. The platform allows patients to view and compare the prices of medical services and surgeries from multiple health providers. It off …
  • Zayo Group LLC (ZAYO):企業の財務・戦略的SWOT分析
    Zayo Group LLC (ZAYO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Chiesi USA Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Chiesi USA Inc (Chiesi USA), a subsidiary of Chiesi Farmaceutici S.p.A, is a specialty pharmaceutical company. It researches, develops, produces and commercializes therapies in cardiovascular, respiratory, neonatology, rare disease and special care therapeutics. The company's product portfol …
  • PHX Minerals Inc (PHX):企業の財務・戦略的SWOT分析
    PHX Minerals Inc (PHX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Concho Resources Inc.:企業の戦略・SWOT・財務分析
    Concho Resources Inc. - Strategy, SWOT and Corporate Finance Report Summary Concho Resources Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Pioneer Distilleries Limited:企業の戦略・SWOT・財務分析
    Pioneer Distilleries Limited - Strategy, SWOT and Corporate Finance Report Summary Pioneer Distilleries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • PPL Corp (PPL):企業の財務・戦略的SWOT分析
    PPL Corp (PPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Pernix Therapeutics Holdings Inc (PTX):医療機器:M&Aディール及び事業提携情報
    Summary Pernix Therapeutics Holdings Inc (Pernix Therapeutics) is a specialty pharmaceutical company that discovers, develops, and markets generic pharmaceutical products. The company’s portfolio encompasses a fixed dose combination product prescribed to treat acute migraine; an extended-release (XR …
  • Xellia Pharmaceuticals ApS:製薬・医療:M&Aディール及び事業提携情報
    Summary Xellia Pharmaceuticals ApS (Xellia), a subsidiary of Novo A/S is a healthcare products provider that offers fermented and semi-synthetic APIs and injectable finished dosage forms. The company offers strain and fermentation development with bacteria and fungi. It provides injectable products …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆